Solid lipid nanoparticles: A novel carrier for chemotherapy

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 2, Issue SUPPL. 3, 2010, Pages 8-17

  Shaji, Jessy ^a   Jain, Vinay ^a  

^a PRIN K M KUNDNANI COLLEGE OF PHARMACY   (India)

Author keywords

Chemotherapy; Nanostructured lipid carriers (NLC); Polymeric lipid hybrid nanoparticles (PLN); Solid lipid nanoparticles (SLN)

Indexed keywords

ANTHRACYCLINE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CARRIER PROTEIN; CYTOTOXIC AGENT; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; ELACRIDAR; EPIPODOPHYLLOTOXIN; EPIRUBICIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; POLOXAMER; POLYMER; RIFAMPICIN; SOLID LIPID NANOPARTICLE; STEARIC ACID; TAMOXIFEN CITRATE; TOPOTECAN; UNINDEXED DRUG; VALSPODAR; VINBLASTINE; VINCRISTINE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD CELL COUNT; CARDIOTOXICITY; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; DRUG STABILITY; DRUG TRANSPORT; DRUG UPTAKE; ENCAPSULATION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GLIOBLASTOMA; HUMAN; HYDROPHILICITY; IMMUNOGENICITY; IN VITRO STUDY; LIPOPHILICITY; LIVER CELL CARCINOMA; LIVER TOXICITY; MOUTH ULCER; NAUSEA AND VOMITING; NEOPLASM; NEUTROPENIA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARASITOSIS; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TUBERCULOSIS;

EID: 77957595695     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (167)

1. Steven MB. Introduction to Chemotherapy. In: Charles RC, Robert ES, editors. Modern Pharmacology with Clinical Application. 5th ed. New York: Lippincott; 2003, p. 509-14.
2. Muller RH. Colloidal carriers for controlled drug delivery and targeting: Modification, characterization and in vivo distribution. CRC Press 1991; 45-55.
3. Muller RH, Dingler A, Schneppe T, Gohla S. Large scale production of solid lipid nanoparticles (SLN™) and nanosuspensions (DissoCubes®). In: Wise D editors. Handbook of Pharmaceutical Controlled Release Technology. 2nd ed. New York: Marcel Dekker; 2000, p. 359-76.
4. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 61-77.
5. Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution. US Patent No. 5250236, 1993.
6. Schwarz C, Mehnert W, Lucks JS, Miiller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery: I. Production, characterization and sterilization. J Control Release 1994; 30: 83-96.
7. Cavalli R, Marengo E, Rodriguez L, Gasco MR. Effects of some experimental factors on the production process of solid lipid nanoparticles. Eur J Pharm Biopharm 1996; 43(2): 110-15.
8. Dong ZH, Chang SX, Kai JH. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 2003; 24: 1781-85.
9. Heiati H, Phillips NC, Tawashi R. Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride. Pharm Res 1996; 13 (9): 140610.
10. Siekmann B, Westesen K. Investigation on solid lipid nanoparticles prepared by precipitation in o/w emulsion. Eur J Pharm Biopharm 1996; 43: 104-09.
11. Hu FQ, Yuan H, Zhang HH, Fang M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm 2002; 239: 121-28.
12. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm 2003; 257: 153-60.
13. Guerrero DQ, Esquivel DT, Quintanar AG. Adaptation and optimization of the emulsification-diffusion technique to prepare lipidic nanospheres. Eur J Pharm Sci 2005; 26: 21118.
14. Yuan H, Huang LF, Du YZ. Solid lipid nanoparticles prepared by solvent diffusion method in a nanoreactor system. Coll Surf B Bioint 2008; 61: 132-37.
15. Schubert MA, Muller CC. Solvent injection as a new approach for manufacturing lipid nanoparticles-evaluation of the method and process parameters. Eur J Pharm Biopharm 2003; 55: 125-31.
16. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165-96.
17. Joshi MD, Muller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009; 71(2): 161-72.
18. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56: 125772.
19. Westesen K, Bunjes H, Koch MHJ. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 1997; 48: 223-36.
20. Wissing SA, Muller RH. Cosmetic applications for solid lipid nanoparticles (SLN). Int J Pharm 2003, 254: 65-68.
21. Miiller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007; 59: 522-30.
22. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54 (Suppl. 1): S131-S155.
23. Wissing SA, Muller RH. Solid lipid nanoparticles as carrier for sunscreens: In vitro release and in vivo skin penetration. J Control Release 2002; 81: 225-33.
24. Chunjin S, Shuangxi L. A new healthy sunscreen system for human: Solid lipid nanoparticles as carrier for 3,4,5-trimethoxybenzoylchitin and the improvement by adding Vitamin E. Int J Bio Macromol 2005; 36: 116-19.
25. Korting MS, Mehnert W, Korting HC. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 2007; 59: 427-43.
26. Lippacher A, Muller RH, Mader K. Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. Int J Pharm 2001; 214: 9-12.
27. Jenning V, Korting MS, Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release 2000; 66: 115-26.
28. Jenning V, Gysler A, Korting MS, Gohla SH. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 2000; 49: 211-18.
29. Muller RH, Maaen S, Weyhers H, Specht F, Lucks JS. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm 1996; 138: 85-94.
30. Peira E, Marzola P, Podio V, Aime S, Sbarbati A, Gasco MR. In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide. J Drug Target 2003; 11: 19-24.
31. Liu W, He Z, Liang J, Zhu Y, Xu H, Yang X. Preparation and characterization of novel fluorescent nanocomposite particles: CdSe/ZnS core-shell quantum dots loaded solid lipid nanoparticles. J Biomed Mater Res 2008; 84: 1018-25.
32. Muller RH, Maassen S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996; 4: 161-70.
33. Muller RH, Maassen S, Schwarz C, Mehnert W. Solid lipid nanopaticles (SLN) as potential carrier for human use: interaction with human granulocytes. J Control Release 1997; 47: 261-69.
34. Westesen K, Siekmann B, Koch MHJ. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm 1993; 93: 189-99.
35. Dingler A, Gohla S. Production of solid lipoid nanoparticles (SLN): Scaling up feasibilities. J Microencapsul 2002; 19: 11-16.
36. Marengo E, Cavalli R, Caputo O, Rodriguez L, Gasco MR. Scale-up of the preparation process of solid lipid nanoparticles. Part I. Int J Pharm 2000; 205: 3-13.
37. Jenning V, Lippacher A, Gohla, SH. Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization. J Microencapsul 2002; 19: 1-10.
38. Gohla SH, Dingler A. Scaling up feasibility of the production of solid lipid nanoparticles (SLN). Pharmazie 2001; 56: 61-63.
39. Cavalli R, Caputo O, Trotta M, Scarnecchia C, Gasco MR. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm 1997; 148: 47-54.
40. Fuentes MG, Torres D, Alonso MJ. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Coll Surf B Bioint 2002; 27: 159-68.
41. Yuan H, Chen J, Du YZ, Hu FQ, Zeng S, Zhao HL. Studies on oral absorption of stearic acid SLN by a novel fluorometric method. Coll Surf B Bioint 2007; 58: 157-64.
42. Fuentes MG, Prego C, Torres D, Alonso MJ. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci 2005; 25: 133-43.
43. Zhang N, Ping Q, Huanga G, Xua W, Chenga Y, Hana X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm 2006; 327: 153-59.
44. Muller RH, Rungea S, Ravelli V, Mehnert W, Souto EB. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm 2006; 317: 82-89.
45. Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis 2005; 85: 415-20.
46. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002; 238: 241-45.
47. Gasco MR, Zara GP, Saettone MF. Pharmaceutical compositions suitable for the treatment of ophthalmic diseases. PCT Int. Appl. WO 2004039351 2004.
48. Attama AA, Reichl S, Muller CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008; 355: 307-13.
49. Li X, Nie S, Kongb J, Li N, Juc C, Pan W. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm 2008; 363: 177-182.
50. Videira MA, Botelho MF, Santos AC, Gouveia LF, Pedroso JJ, Almeida AJ. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target 2002; 8: 607-613.
51. Chattopadhyay P, Shekunov BY, Yim D, Cipolla D, Boyd B, Farr S. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Deliv Rev 2007; 6: 444-53.
52. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 2008; 356: 333-44.
53. Sznitowska M, Gajewska M, Janicki S, Radwanska A, Lukowski G. Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur J Pharm Biopharm 2001; 52: 159-63.
54. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999; 59: 299-307.
55. Ratain MJ, Mick R. Principles of pharmacokinetics and pharmacodynamics. In: Schilsky RL, Milano GA, Ratain MJ editors. Principles of Antineoplastic Drug Development and Pharmacology. New York: Marcel Dekker; 1996, p. 123-42.
56. Lowenthal RM, Eaton K. Toxicity of chemotherapy. Hematol Oncol Clin North Am. 1996; 10: 967-90.
57. Tipton JM. Side effects of cancer chemotherapy. In: Skeel RT editors. Handbook of Cancer Chemotherapy. Philedelphia: Lippincott Williams & Wilkins; 2003, p. 561-80.
58. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 2002; 234: 119-24.
59. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Cancer Sci 2000; 11: 265-83.
60. Links M, Brown R. Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev Mol Med 1999; 1-21.
61. Gieseler F, Rudolph P, Kloeppel G, Foelsch UR. Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail? Int J Colorectal Dis 2003; 18: 470-80.
62. Baird RD, Kaye SB. Drug resistance reversal-are we getting closer? Eur J Cancer 2003; 39: 2450-61.
63. Safa AR. Multidrug resistance. In: Schilsky RL, Milano GA, Ratain MJ editors, Principles of Antineoplastic Drug Development and Pharmacology. New York: Marcel Dekker; 1996, p. 457-86.
64. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986; 6: 193-10.
65. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissue. Jpn J Can Res 1998; 89: 307-14.
66. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discovery Today 2006; 11: 812-18.
67. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001; 46: 169-85.
68. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Advan Enzyme Regul 2001; 41: 189-207.
69. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000; 65: 271-84.
70. Arnaud B, Saulniera P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials 2007; 28: 4947-67.
71. Byrne JD, Betancourt T, Peppas LB. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008; 60: 1615-26.
72. Wanga JX, Sunb X, Zhang ZR. Enhanced brain targeting by synthesis of 30,50-dioctanoyl-5-fluoro-20-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm 2002; 54: 285-90
73. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008; 127: 97-109
74. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 2007; 59: 454-77.
75. Messerschmidt SK, Musyanovych A, Altvater M, Scheurich P, Pfizenmaier K. Targeted lipid-coated nanoparticles: Delivery of tumor necrosis factor-functionalized particles to tumor cells. J Control Release 2009; 137: 69-77.
76. Muller RH, Lippacher A, Gohla, S. Solid lipid nanoparticles (SLN) as carrier system for the controlled release of drugs. In: Wise D editors. Handbook of Pharmaceutical Controlled Release Technology. New York: Marcel Dekker; 2000, p. 37791.
77. Souto EB, Muller RH. Lipid nanoparticles (solid lipid nanoparticles and nanostructured lipid carriers) for cosmetic, dermal and transdermal applications, In: D Thassu, M Deleers, Y Pathak editors. Nanoparticulate Drug Delivery Systems: Recent Trends and Emerging Technologies. CRC Press; 2007, p. 213-33.
78. Muller RH, Mehnert W, Souto EB. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for dermal delivery. In: Bronaugh L editors, Percutaneous Absorption. New York: Marcel Dekker; 2005, p. 719-38.
79. Morel S, Gasco MR, Cavalli R. Incorporation in lipospheres of [D-Trp-6] LHRH. Int. J. Pharm. 1994; 105: R1-R3.
80. Balmer CM, Valley AW. Cancer treatment and chemotherapy. In: Dipiro JT, Talbert RC, Yee GC, Matzke GR, Wells BG editors. Pharmacotherapy - A Pathophysiologic Approach. 5th ed. Canada: Prentice Hall, Toronto; 2002, p. 2175-2222.
81. Cavalli R, Caputo O, Gasco MR. Solid lipospheres of doxorubicin and idarubicin, Int J Pharm 1993; 89: R9-R12.
82. Olbrich C, Gebner A, Kayser O, Muller RH. Lipid-drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazene diaceturate. J Drug Target 2002; 10: 387-96.
83. Wong HL, Bendayan R, Rauth AM, Wu XY. Development of solid lipid nanoparticles containing ionically-complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci 2004; 93: 1993-2004.
84. Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu Z et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug resistant human breast cancer cells. Pharm Res 2006; 23: 1574-85.
85. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle (PLN) system. J Pharmacol Exp Ther 2006; 317: 1372-81.
86. Li Y, Taulier N, Rauth AM, Wu XY. Screening of lipid carriers and characterization of drug-polymer complex for the rational design of polymer-lipid hybrid nanoparticles. Pharm Res 2006; 23: 1877-87.
87. Liu Z, Cheung R, Bendayan R, Ballinger J, Rauth M, Wu XY. A study of doxorubicin loading onto and release from sulfopropyl dextran ion-exchange microspheres. J Control Release 2001; 77: 213-24.
88. Cheung RY, Kuba B, Rauth AM, Ying Y, Wu XY. A new approach to the in vivo-in vitro correlation of drug release from locoregionally delivered microspheres. J Control Release 2004; 100: 121-33.
89. Liu Z, Ballinger J, Rauth M, Bendayan R, Wu XY. Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres. J Pharm Pharmacol 2003; 55: 1063-73.
90. Cheung R, Ying Y, Wu XY, Rauth AM, Marcon N. Microsphere delivered mitomycin C and the effects on cancer cells of combining mitomycin C and doxorubicin. J Control Release 2003; 91: 240-42.
91. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003, 42: 46378.
92. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002; 4: 95-99.
93. Gabizon AA, Muggia FM, Woodle MC, Storm G. Long Circulating Liposomes: Old Drugs, New Therapeutics Springer-Verlag and Landes Bioscience 1998; 155-74.
94. Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: Pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 2002; 10: 327-35.
95. Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after IV administration to rats. Pharm Res 2000; 42: 337-43.
96. Cavalli R, Caputo O, Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci 2000; 10: 305-09.
97. Muhlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 1998; 45: 149-55.
98. Bunjes H, Westesen K, Koch MHJ. Crystallization tendency and polymorphic transition in triglyceride nanoparticles. Int J Pharm 1996; 129: 159-73.
99. Siekmann B, Westesen K. Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles. Coll Surf B Bioint 1994; 3: 159-75.
100. Freitas C, Muller RH. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm 1999; 47: 125-32.
101. Muller RH, Schwarz C, Muhlen A, Mehnert W. Incorporation of lipophilic drugs and release profiles of solid lipid nanoparticles (SLN). Proc Int Symp Control Release Bioact Mater 1994; 21: 146-47.
102. Wong HL, Li Y, Bendayan R, Rauth MA, Wu XY. Solid lipid nanoparticles for antitumor drug delivery, In: Amiji M editors. Nanotechnology for Cancer Therapy. CRC Press; 2006, p. 71476.
103. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-82.
104. Yang SC, Zhu JB. Preparation and characterization of camptothecan solid lipid nanoparticles. Drug Dev Ind Pharm 2002; 28: 265-74.
105. Podio V, Zara GP, Carazzonet M, Cavalli R, Gasco MR. Biodistribution of stealth and non-stealth solid lipid nanospheres after intravenous administration to rats. J Pharm Pharmacol 2000; 52: 1057-63.
106. Bargoni A, Cavalli R, Caputo O, Fundaro A, Gasco MR, Zara GP. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 1998; 15: 745-50.
107. Chen DB, Yang TZ, Lu WL, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull 2001; 49: 1444-47.
108. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 2004; 99: 259-69.
109. Koziara JM, Whisman TR, Tseng MT, Mumper RJ. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Release 2006; 112: 312-19.
110. Lee MK, Lim SJ, Kim CK. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007; 28: 2137-46.
111. Chen D, Yang T, Lu W, Zhang Q. In vitro and in vivo study of two kinds of long-circulating solid lipid nanoparticles containing paclitaxel. Acta Pharm Sin 2002; 37: 54-58.
112. Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm 2008; 348: 137-45.
113. Miglietta A, Cavalli R, Bocca C, Gabriel L, Gasco MR. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel, Int J Pharm 2000; 210: 61-67.
114. Serpe L, Catalano MG, Cavalli R, Canaparo R, Gasco MR, Zara GP,et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 2004; 58: 673-80.
115. Zhang XG, Miao J, Dai YQ, Du YZ, Yuan H, Hu FQ. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm 2008; 361: 239-44.
116. Fontana G, Maniscalco L, Schillaci D, Cavallaro G, Giammona G. Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity. Drug Deliv 2005; 12: 385-92.
117. Reddy LH, Vivek K, Bakshi N, Murthy RS. Tamoxifen citrate loaded solid lipid nanoparticles (SLN): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm Dev Technol 2006; 11: 167-77.
118. Wong HL, Bendayan R, Rauth AM, Wu XY. Formulation, characterization and in vitro cytotoxicity of solid lipid nanoparticles carrying polymer-linked doxorubicin and GG918, a novel P-glycoprotein inhibitor AAPS J 2004; 6.
119. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
120. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137-71.
121. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615-27.
122. Millenbaugh NJ, Wientjes MG, Au JLS. A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect. Cancer Chemother Pharmacol 2000; 45: 265-72.
123. Wong HL, Bendayan R, Rauth AM, Wu XY. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm 2007; 65: 300-308.
124. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
125. Gueritte VF, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P, et al. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991; 34: 992-98.
126. Wenzel C, Locker GJ, Schmidinger M, Rudas M, Taucher S, Gnant MF, et al.Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel plus granulocyte colony stimulating factor. Anticancer Drugs 2002; 13: 67-74.
127. Cascinu S, Graziano F, Barni S, Labianca R, Comella G, Casaretti R, et al. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Br J Cancer 2001; 84: 470-4.
128. Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, et al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002; 94: 97-103.
129. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA. Phase II evaluation of docetaxel plus oneday oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002; 94: 1457-65.
130. Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009; 30: 226-32.
131. Terada T, Iwai M, Kawakami S, Yamashita F, Hashida M. Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. J Control Release 2006; 111: 333-42.
132. Managit C, Kawakami S, Yamashita F, Hashida M. Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells. Int J Pharm 2005;301: 255-61
133. Lu B, Xiong SB, Yang H, Yin XD, Chao RB, Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur J Pharm Sci 2006; 28: 86-95.
134. Phillips WT, Klipper R, Goins B. Novel method of greatly enhanced delivery of liposomes to lymph nodes. J Parmacol Exp Ther 2000; 295(1): 309-13.
135. Ashley D, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 1996; 14: 1922-27.
136. Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RSR. Etoposide incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies. AAPS J 2004; 6: 23.
137. Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RSR. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J Control Release 2005; 105: 185-98.
138. Reddy LH, Adhikari JS, Dwarakanath BSR, Sharma RK, Murthy RR. Tumoricidal Effects of Etoposide Incorporated Into Solid Lipid Nanoparticles After Intraperitoneal Administration in Dalton ' s Lymphoma Bearing Mice. The AAPS Journal 2006; 8 (2): Article 29
139. Yu BT, Zhang ZR, Zeng RJ. Study on the liver targeted 5-fluorouracil solid lipid nanoparticles Yaoxue Xuebao 2000; 35: 704-5.
140. Lim SJ, Lee MK, Kim CK. Altered chemical and biological activities of all trans retinoic acid incorporated in solid lipid nanoparticle powders. J Control Release 2004; 100: 53-61.
141. Wan F, You J, Sun Y, Zhang XG, Cui FD, Du YZ, Yuan H, Hu FQ. Studies on PEG-modified SLN loading vinorelbine bitartrate (I): preparation and evaluation in vitro. Int J Pharm 2008;359: 104-10.
142. Bondi ML, Craparo EF, Giammona G, Cervello M, Azzolina A, Diana P, et al. Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies. Drug Deliv. 2007; 14; 61-67
143. Oyewumi MO, Yokel RA, Jay M, Coakley T, Mumper RJ. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J Control Release 2004; 95: 613-26.
144. Edwards G, Krishna S. Pharmacokinetic and pharmacodynamic issues in the treatment of parasitic infections. Eur J Clin Microbiol Infect Dis 2004; 23: 233-42.
145. http://www.who.int/tdr/diseases/default.htm accessed on 31st Jan 2010.
146. Watkins B. Drugs for the control of parasitic diseases: current status and development, Trends Parasitol 2003; 19: 477-78.
147. Date AA, Joshi MD, Patravale VB. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Revi 2007; 59: 505-21.
148. Zara G, Bargoni A, Cavalli R, Fundar A, Vighetto D, Gasco M. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 2002; 91: 1324-33.
149. Gupta Y, Jain A, Jain SK. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol 2007; 59: 935-40.
150. Olbrich C, Gessner A, Schroder W, Kayser O, Muller RH. Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption. J Control Release 2004; 96: 425-35.
151. Gessner A, Olbrich C, Schroeder W, Kayser O, Muller R. The role of plasma proteins in brain targeting: species dependant protein adsorption patterns on brain specific lipid drug conjugate (LDC) nanoparticles. Int J Pharm 2001; 214: 87-91.
152. Joshi MD, Patravale VB. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: nanoject. Int J Pharm 2008; 364: 11926.
153. Pandey R, Sharma S, Khuller GK. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis. Int J Antimicrob Agents 2004; 23: 414-15.
154. Pandey R, Zahoor A, Sadhna S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 2003; 83: 373-78.
155. Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular Chemotherapy. Tuberculosis 2005; 85,: 415-20.
156. Pandey R, Khuller GK. Solid lipid nanoparticle based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis, 2005; 85: 227-34.
157. Stevens PJ, Sekido M, Lee RJ. A folate-receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug, Pharm Res 2004; 21: 2153-57.
158. Templeton NS. Cationic liposome-mediated gene delivery in vivo. Biosci Rep 2002; 22: 283-95.
159. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U. S. A. 1995; 92: 7297301.
160. Gottschalk S, Sparrow JT, Hauer J, Mims MP, Leland FE, Woo SLC, Smith LC. A novel DNA-peptide complex for efficient gene transfer and expression in mamalian cells. Gene Ther 1996; 3: 448-57.
161. Haensler J, Szoka FC Jr. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 1993; 4: 372-79.
162. Ciftci K, Levy RJ. Enhanced plasmid DNA transfection with lysosomotropic agents in cultured fibroblasts. Int J Pharm 2001; 218: 81-92.
163. Tabatt K, Kneuer C, Sameti M, Olbrich C, Muller RH, Lehr CM, Bakowsky U. Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J Control Release 2004; 97: 321-32.
164. Tabatt K, Sameti M, Olbrich C, Muller RH, Lehr CM. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticlemediated gene transfer. Eur J Pharm Biopharm 2004; 57: 155-62.
165. Fischer V, Gascon AR, Heitz F, Tynes R, Hauck C, Cohen D, Vickers AEM. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A: implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 1998; 26: 802-11.
166. Verweij J. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol 2005; 55: 91-99.
167. Ahmadian S, Fakhree MAA. Lipid based nanoparticles containing saturated solution of NaCl, may be used to targeted eradication of cancerous cells, short communication. Biosci Hypo 2009; 2: 172-3.